menu search

DMTK / Why DermTech Still Has Ten-Bagger Potential

Why DermTech Still Has Ten-Bagger Potential
Skin-cancer detection could lead to big returns for this stock. Read More
Posted: Dec 4 2021, 08:30
Author Name: The Motley Fool
Views: 092054

DMTK News  

DermTech, Inc. (DMTK) Q2 2023 Earnings Call Transcript

By Seeking Alpha
August 3, 2023

DermTech, Inc. (DMTK) Q2 2023 Earnings Call Transcript

DermTech, Inc. (NASDAQ:DMTK ) Q2 2023 Earnings Conference Call August 3, 2023 5:00 PM ET Company Participants Steve Kunszabo - Head, Investor Relation more_horizontal

If You Own These 3 Growth Stocks, You Might Want to Rethink Your Position

By The Motley Fool
June 20, 2023

If You Own These 3 Growth Stocks, You Might Want to Rethink Your Position

Nano-X is marketing a different type of X-ray system. DermTech's Smart Sticker system could change dermatology. more_horizontal

DermTech, Inc. (DMTK) Reports Q1 Loss, Lags Revenue Estimates

By Zacks Investment Research
May 4, 2023

DermTech, Inc. (DMTK) Reports Q1 Loss, Lags Revenue Estimates

DermTech, Inc. (DMTK) came out with a quarterly loss of $1.02 per share versus the Zacks Consensus Estimate of a loss of $0.90. This compares to loss more_horizontal

DermTech, Inc. (DMTK) Q4 2022 Earnings Call Transcript

By Seeking Alpha
March 2, 2023

DermTech, Inc. (DMTK) Q4 2022 Earnings Call Transcript

DermTech, Inc. (NASDAQ:DMTK ) Q4 2022 Earnings Conference Call March 2, 2023 5:00 PM ET Company Participants Steve Kunszabo - Head of IR John Dobak - more_horizontal

DermTech, Inc. (DMTK) Reports Q4 Loss, Tops Revenue Estimates

By Zacks Investment Research
March 2, 2023

DermTech, Inc. (DMTK) Reports Q4 Loss, Tops Revenue Estimates

DermTech, Inc. (DMTK) delivered earnings and revenue surprises of 3.12% and 19.52%, respectively, for the quarter ended December 2022. Do the numbers more_horizontal

DermTech: Momentum Rising With TRICARE

By Seeking Alpha
January 22, 2023

DermTech: Momentum Rising With TRICARE

The company's skin diagnostic test, dubbed DMT, has an uncanny ability to pick up the highly prevalent skin cancer, melanoma. Commercialization has be more_horizontal

This Under-the-Radar Stock Has Tripled in 2023 -- and Could Have More Room to Run

By The Motley Fool
January 18, 2023

This Under-the-Radar Stock Has Tripled in 2023 -- and Could Have More Room to Run

This beaten-down healthcare stock has started the new year off with a bang. more_horizontal

DermTech, Inc. (DMTK) CEO John Dobak on Q2 2022 Results - Earnings Call Transcript

By Seeking Alpha
August 8, 2022

DermTech, Inc. (DMTK) CEO John Dobak on Q2 2022 Results - Earnings Call Transcript

DermTech, Inc. (NASDAQ:DMTK ) Q2 2022 Earnings Conference Call August 8, 2022 5:00 PM ET Company Participants Steve Kunszabo - Head of Investor Relati more_horizontal


Search within

Pages Search Results: